Safety Analysis of Axatilimab in Patients with Chronic Graft-Versus-Host Disease in an Expanded Access Program

Key Points

• Patient outcomes indicate manageable adverse events associated with axatilimab treatment, supporting its use.
• In the expanded access program, the safety analysis showed a low incidence of severe complications during treatment.
• Comprehensive safety profiles were assessed with regular monitoring of immune responses in patients receiving axatilimab.
• Findings highlight the need for further studies to validate long-term efficacy and safety in diverse populations.